Assessing dengue vaccination impact: Model challenges and future directions.

In response to the sharp rise in the global burden caused by dengue virus (DENV) over the last few decades, the WHO has set out three specific key objectives in its disease control strategy: (i) to estimate the true burden of dengue by 2015; (ii) a reduction in dengue mortality by at least 50% by 2020 (used as a baseline); and (iii) a reduction in dengue morbidity by at least 25% by 2020. Although various elements will all play crucial parts in achieving this goal, from diagnosis and case management to integrated surveillance and outbreak response, sustainable vector control, vaccine implementation and finally operational and implementation research, it seems clear that new tools (e.g. a safe and effective vaccine and/or effective vector control) are key to success. The first dengue vaccine was licensed in December 2015, Dengvaxia® (CYD-TDV) developed by Sanofi Pasteur. The WHO has provided guidance on the use of CYD-TDV in endemic countries, for which there are a variety of considerations beyond the risk-benefit evaluation done by regulatory authorities, including public health impact and cost-effectiveness. Population-level vaccine impact and economic and financial aspects are two issues that can potentially be considered by means of mathematical modelling, especially for new products for which empirical data are still lacking. In December 2014 a meeting was convened by the WHO in order to revisit the current status of dengue transmission models and their utility for public health decision-making. Here, we report on the main points of discussion and the conclusions of this meeting, as well as next steps for maximising the use of mathematical models for vaccine decision-making

Characterisation of Medipix3 Silicon Detectors in a Charged-Particle Beam

While designed primarily for X-ray imaging applications, the Medipix3 ASIC can also be used for charged-particle tracking. In this work, results from a beam test at the CERN SPS with irradiated and non-irradiated sensors are presented and shown to be in agreement with simulation, demonstrating the suitability of the Medipix3 ASIC as a tool for characterising pixel sensors.Comment: 16 pages, 13 figure

Hadron formation in high energy photonuclear reactions

We present a new method to account for coherence length effects in a semi-classical transport model. This allows us to describe photo- and electroproduction at large nuclei (A>12) and high energies using a realistic coupled channel description of the final state interactions that goes beyond simple Glauber theory. We show that the purely absorptive treatment of the final state interactions can lead to wrong estimates of color transparency and formation time effects in particle production. As an example, we discuss exclusive rho^0 photoproduction on Pb at a photon energy of 7 GeV as well as K^+ production in the photon energy range 1-7 GeV.Comment: 14 pages, 6 figures, version published in Phys. Rev.

VON DER INTERDISZIPLINÄREN GRUNDLAGENFORSCHUNG ZUR COMPUTERVISUALISTISCHEN ANWENDUNG: DIE MAGDEBURGER BEMÜHUNGEN UM EINE ALLGEMEINE WISSENSCHAFT VOM BILD

Seit den ersten Höhlenzeichnungen haben bildhafte Darstellungen für Menschen eine zwar immer umstrittene, aber doch nie entbehrliche Orientierungsaufgabe besessen. Das Bild geriet hierbei oft in Konkurrenz zur Schrift: Als Ausdruck abstrakter Gedanken war es jener unterlegen, doch wurde ihm im Gegenzug eine geradezu magische Aura zugesprochen. Diese ambivalente Haltung den Bildern gegenüber hatte zur Folge, dass alle Erfindungen neuer Bildmedien immer zugleich höchste Begeisterung wie tiefste Skepsis hervorriefen. Sie ist vermutlich ebenfalls dafür verantwortlich, dass sich bis heute eine einheitliche und im strengeren Sinn wissenschaftliche Erforschung der Bilder nicht etablieren konnte. Im vorliegenden Aufsatz werden die Bemühungen skizziert, die hierzu in jüngster Zeit an der Magdeburger Universität unternommen worden sind. Damit verbunden, möchten wir unseren Vorschlag einer Konzeption von Bildwissenschaft zur Diskussion stellen

Maternal smoking and high BMI disrupt thyroid gland development

This study was supported by grants from the Medical Research Council (MR/L010011/1) (to PAF & PJOS), the Natural Science and Engineering Research Council of Canada (NSERC) for TK and SHK, and NHS Endowment Grant (to PF).Peer reviewedPublisher PD

Pion-Production in Heavy-Ion Collisions at SIS energies

We investigate the production of pions in heavy-ion collisions in the energy range of $1$ - $2$ GeV/A. The dynamics of the nucleus-nucleus collisions is described by a set of coupled transport equations of the Boltzmann-Uehling-Uhlenbeck type for baryons and mesons. Besides the $N(938)$ and the $\Delta(1232)$ we also take into account nucleon resonances up to masses of $1.9 GeV/c^2$ as well as $\pi$-, $\eta$- and $\rho$-mesons. We study in detail the influence of the higher baryonic resonances and the $2\pi$-production channels ($NN\to NN \pi\pi$) on the pion spectra in comparison to $\pi^-$ data from $Ar + KCl$ collisions at $1.8$ GeV/A and $\pi^0$-data for $Au+Au$ at 1.0 GeV/A. We, furthermore, present a detailed comparison of differential pion angular distributions with the BEVALAC data for Ar + KCl at 1.8 GeV/A. The general agreement obtained indicates that the overall reactions dynamics is well described by our novel transport approach.Comment: 31 pages, 18 figures (inlcuded), to appear in Z. Phys.

Developing a vaccine against Zika

The race to develop a vaccine against Zika began in February 2016, when the unusual clustering of cases of microcephaly and other neurological disorders associated with Zika virus infection led to the declaration of a public health emergency of international concern. When the World Health Organization held its first consultation in March, 14 active vaccine projects had already been announced.1 Today, WHO’s pipeline tracker counts about 30 active projects, pursued by developers from endemic and non-endemic countries, private and public sector.2 Such a jump start in vaccine development is rare, and several candidates have already progressed to clinical development. This pace is facilitated by our collective experience in developing vaccines against flaviviruses, the availability of novel vaccine technologies that greatly facilitate manufacturing of vaccines appropriate for trials in humans, and generous funding from some governments to support both basic research and product development